All In Biotech

Drug Trial Radar · NCT04123626

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene

A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene

Last checked: Nov 20, 2026Latest source record: May 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

11

Actual

Start

Oct 7, 2019

Primary completion

Jun 7, 2022

Study completion Jun 7, 2022

Sponsor

Lead sponsor
ProQR TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety, tolerability and efficacy of QR-1123 injection in the eye (intravitreal; IVT) injections (one eye/unilateral) in subjects receiving a single dose or repeat doses. Single injections will be assessed in an open label way, and repeat injections will be assessed in a double-masked, randomized, sham-controlled fashion.

Conditions

  • Autosomal Dominant Retinitis Pigmentosa
  • Eye Diseases
  • Eye Diseases, Hereditary
  • Retinal Dystrophies
  • Retinal Disease
  • Retinitis
  • Vision Tunnel
  • Vision Disorders

Interventions

  • QR-1123Drug

    unilateral IVT injection

  • Sham procedureOther

    Sham procedures (i.e. no penetration of the globe) closely mimic the active injection and serve to mask subjects to treatment assignment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of ocular AEsTime frame: up to 12 months
  2. Incidence and Severity of non-ocular AEsTime frame: up to 12 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Sue Anschutz-Rogers Eye Center, University of Colorado - Dept. of Ophthalmology

    Aurora, Colorado

  • VitreoRetinal Associates

    Gainesville, Florida

  • Shriners UK Ophthalmology - University of Kentucky

    Lexington, Kentucky

  • Casey Eye Institute, OHSU

    Portland, Oregon

  • Retina Foundation of the Southwest

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.